Tag: eltrombopag

FDA expands scope of Novartis’ Promacta

by Selina McKee | Nov 19, 2018 | News | 0

US regulators have expanded the scope of Novartis’ Promacta to include earlier use of the drug to treat adults and paediatric patients with severe aplastic anaemia (SAA) in combination with standard immunosuppressive therapy (IST).

Data back first-line use of Novartis’ eltrombopag in SAA

by Selina McKee | Apr 20, 2017 | News | 0

Novartis has announced the publication of data showing high response rates in patients with the rare blood disorder severe aplastic anaemia (SAA) taking its medicine eltrombopag, supporting its first-line use for the condition.